公司概述
Jaguar Health, Inc. operates as a commercial-stage pharmaceuticals company dedicated to the development of plant-based prescription medicines designed to alleviate gastrointestinal distress in both human patients and animals. The enterprise functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on innovation-driven product pipelines and regulatory compliance for novel therapeutic agents. The company's market capitalization stands at $4.71M, while its annual revenue over the trailing twelve months is recorded at $11.51M. The employee count is listed as N/A, indicating that specific headcount data is not currently disclosed in public filings or available datasets. These valuation and revenue figures suggest that the company maintains a very small market presence, reflecting the early-to-mid stage nature of its operations where revenue generation is constrained by the developmental status of its product portfolio.
财务健康
The company reported a trailing twelve-month revenue of $11.51M, yet this generated a net income of $-53,575,000, revealing a significant structural gap where operating expenses and research costs vastly exceed top-line earnings. The EBITDA for the same period was $-43,195,000, further highlighting the intense burn rate associated with developing pre-commercial pharmaceutical products. Free cash flow stood at $-15,446,375, which indicates that the company is utilizing its remaining cash reserves to fund operations and development rather than generating internal liquidity. Gross margin is calculated at 67.2%, suggesting that the cost of goods sold is relatively low compared to revenue, a common characteristic in the biotechnology sector prior to full commercialization. However, the operating margin is severely negative at -631.9%, and the profit margin is effectively 0.0%, indicating that overhead costs and R&D expenditures are disproportionately high relative to sales. The company holds $968,000 in cash against $43.61M in debt, resulting in a debt-to-equity ratio that is listed as N/A due to the equity structure. This balance sheet configuration represents a highly leveraged position where debt obligations significantly outweigh available liquid assets. The current ratio is 0.50, meaning the company possesses less than half the current assets required to cover its current liabilities, signaling potential short-term liquidity constraints. Return on Equity is N/A, while Return on Assets is -61.5%, demonstrating that the asset base is currently generating negative returns rather than value for shareholders.
估值评估
The trailing P/E ratio is not applicable (N/A) due to the lack of positive net income, whereas the forward P/E is listed as -0.07, implying that future earnings expectations remain negative in the near term. The price-to-book ratio is 0.44, indicating that the market values the company at less than half of its net asset book value. The price-to-sales ratio is 0.41, suggesting a valuation multiple relative to revenue that is low but reflects the high-risk profile of a biotech firm with no profitable history. The enterprise value to EBITDA stands at -1.13, which is an alternative metric that also reflects negative earnings power and a lack of traditional operational profitability. The stock has traded between a 52-week low of $0.31 and a 52-week high of $15.48, showing extreme volatility in its trading range. Given the current market conditions and the company's financial status, the trading price sits well below the 52-week high of $15.48, reflecting a significant discount relative to its recent peak performance. The beta value is N/A, meaning that the stock's price volatility relative to the broader market cannot be quantified with standard statistical measures based on the available data.
Growth & Income
Revenue growth year-over-year is -7.8%, while earnings growth year-over-year is N/A due to the company's continued losses. The negative revenue growth indicates a contraction in top-line sales, which occurs faster than any hypothetical earnings growth since earnings are negative and volatile. As a non-dividend payer, the company does not distribute a dividend yield, which is listed as N/A, nor does it have a payout ratio, as this is recorded at 0.0%. Consequently, the company is not returning capital to shareholders through dividends but is instead retaining all earnings to reinvest into its research and development pipeline for gastrointestinal medicines. The overall growth and income profile is characterized by a shrinking revenue base and a complete absence of current income generation or dividend payouts, typical for a commercial-stage pharmaceutical company still navigating the challenges of market entry and product approval.